(R)-2-((2-bromo-5-((furan-2-ylmethyl)thio)thiazolo[4,5-d]pyrimidin-7-yl)amino)propan-1-ol | 1034142-95-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: (R)-2-((2-bromo-5-((furan-2-ylmethyl)thio)thiazolo[4,5-d]pyrimidin-7-yl)amino)propan-1-ol
• CAS: 1034142-95-4
• 化学式: C₁₃H₁₃BrN₄O₂S₂
• 分子量: 401.308
• InChiKey: JDJUKSAYSINRIW-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.53
• 重原子数：
  22.0
• 可旋转键数：
  6.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  84.07
• 氢给体数：
  2.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  甲醇 、 (R)-2-((2-bromo-5-((furan-2-ylmethyl)thio)thiazolo[4,5-d]pyrimidin-7-yl)amino)propan-1-ol 在 氢氧化钾 作用下， 以79%的产率得到(R)-2-((5-((furan-2-ylmethyl)thio)-2-methoxythiazolo[4,5-d]pyrimidin-7-yl)amino)propan-1-ol
  参考文献：
  名称：

  Evaluation of a series of bicyclic CXCR2 antagonists

  摘要：

  The CXCR2 SAR of a series of bicyclic antagonists such as the 2-aminothiazolo[4,5-d]pyrimidine 3b was investigated by systematic variation of the fused pyrimidine-based heterocyclic cores. Replacement of the aminothiazole ring with a 2-thiazolone alternative led to a series of thiazolo[4,5-d]pyrimidine-2(3H)-one antagonists with markedly improved biological and pharmacokinetic properties, which are suitable pharmacological tools to probe the in vivo effects of CXCR2 antagonism combined with the associated CCR2 activity. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.039
• 作为产物：
  描述：

  (2R)-2-[[2-Amino-5-[(2-furanylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-propanol 在 三溴甲烷 、 亚硝酸异戊酯 作用下， 以 二甲基亚砜 为溶剂， 生成 (R)-2-((2-bromo-5-((furan-2-ylmethyl)thio)thiazolo[4,5-d]pyrimidin-7-yl)amino)propan-1-ol
  参考文献：
  名称：

  Evaluation of a series of bicyclic CXCR2 antagonists

  摘要：

  The CXCR2 SAR of a series of bicyclic antagonists such as the 2-aminothiazolo[4,5-d]pyrimidine 3b was investigated by systematic variation of the fused pyrimidine-based heterocyclic cores. Replacement of the aminothiazole ring with a 2-thiazolone alternative led to a series of thiazolo[4,5-d]pyrimidine-2(3H)-one antagonists with markedly improved biological and pharmacokinetic properties, which are suitable pharmacological tools to probe the in vivo effects of CXCR2 antagonism combined with the associated CCR2 activity. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.039